S66 — Star Combo Pharma Share Price
0.000.00%
Last trade - 00:00- AU$15.53m
- AU$6.71m
- AU$26.28m
- 74
- 91
- 48
- 80
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.46 | ||
| Price to Tang. Book | 0.47 | ||
| Price to Free Cashflow | 3.75 | ||
| Price to Sales | 0.52 | ||
| EV to EBITDA | 2.91 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 2.92% | ||
| Return on Equity | 2.68% | ||
| Operating Margin | 3.74% | ||
Financial Summary
| Year End 30th Jun | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | AU$m | 39.08 | 27.08 | 23.91 | 24.99 | 26.28 | n/a | n/a | 4.01% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Star Combo Pharma Limited is an Australia-based distributor and manufacturer of branded premium health and natural beauty products. The Company operates through two segments: the Star Combo business and the Austoyou retail business. The Star Combo business segment is engaged in the business of development, manufacturing, marketing and sales of natural health supplements and skin care products (OEM Division). The Austoyou retail business is made up of the Australia-China e-commerce platform that offers over 700 high-demand product lines directly to Chinese health product consumers. The Company’s product categories include Costar, Living Healthy, Amax and J&K. The Company also provides Original Equipment Manufacturer (OEM) Services and Quality Assurance. The Company’s wholly-owned subsidiaries include CoStar Pharma Laboratory Pty Ltd, Star Combo Australia Pty Ltd, Austoyou Group Pty Ltd, and Koala Mall Pty Ltd.
Directors
- Richard Allely NEC
- Su Zhang CEO
- Daniel Zheng CFO
- Star Zhang MDR
- Patrick Raper SEC
- Jialong Ding NED
- Wei Han NED
- Ziye Sui NED (42)
- Last Annual
- June 30th, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- November 4th, 2016
- Public Since
- May 16th, 2018
- Sector
- Specialty Retailers
- Industry
- Consumer Cyclicals
- Exchange
- Australian Stock Exchange - SEATS
- Shares in Issue
- 135,082,901
- Address
- Smithfield, 171 - 177 Woodpark Road, Sydney, 2164
- Web
- https://www.starcombo.com.au/
- Phone
- +61 297566555
- Auditors
- GCC Business & Assurance Pty Ltd
Upcoming Events for S66
Similar to S66
Accent
Australian Stock Exchange - SEATS
Adairs
Australian Stock Exchange - SEATS
Autosports
Australian Stock Exchange - SEATS
Baby Bunting
Australian Stock Exchange - SEATS
Beacon Lighting
Australian Stock Exchange - SEATS
FAQ
What is the Star Combo Pharma share price?
As of Today at 23:26 UTC, shares in Star Combo Pharma are trading at AU$0.12. This share price information is delayed by 15 minutes.
How has the Star Combo Pharma share price performed this year?
Shares in Star Combo Pharma last closed at AU$0.12 and the price had moved by -4.17% over the past 365 days. In terms of relative price strength the Star Combo Pharma share price has underperformed the ASX All Ordinaries Index by -7.64% over the past year.
What are the analyst and broker recommendations for Star Combo Pharma?
There is no consensus recommendation for this security.
Find out moreWhat is the Star Combo Pharma dividend yield?
The Star Combo Pharma dividend yield is 3.22% based on the trailing twelve month period.
Does Star Combo Pharma pay a dividend?
Last year, Star Combo Pharma paid a total dividend of AU$0.00, and it currently has a trailing dividend yield of 3.22%. We do not have any data on when Star Combo Pharma is to next pay dividends.
When does Star Combo Pharma next pay dividends?
We do not have data on when Star Combo Pharma is to next pay dividends. The historic dividend yield on Star Combo Pharma shares is currently 3.22%.
How do I buy Star Combo Pharma shares?
To buy shares in Star Combo Pharma you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Star Combo Pharma?
As of the previous close price of AU$0.12, shares in Star Combo Pharma had a market capitalisation of AU$15.53m.
Where are Star Combo Pharma shares listed?
Here are the trading details for Star Combo Pharma:
- Country of listing: Australia
- Exchange: ASX
- Ticker Symbol: S66
What kind of share is Star Combo Pharma?
Based on an overall assessment of its quality, value and momentum Star Combo Pharma is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Star Combo Pharma share price forecast for 2025?
We could not find analyst target price data for this security.
Find out moreWhat is the trend in the Star Combo Pharma share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Star Combo Pharma. Over the past six months, its share price has underperformed the ASX All Ordinaries Index by -26.06%.
As of the last closing price of AU$0.12, shares in Star Combo Pharma were trading -21.19% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Star Combo Pharma PE Ratio?
The Star Combo Pharma PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at AU$0.12.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Star Combo Pharma?
Star Combo Pharma's management team is headed by:
- Richard Allely - NEC
- Su Zhang - CEO
- Daniel Zheng - CFO
- Star Zhang - MDR
- Patrick Raper - SEC
- Jialong Ding - NED
- Wei Han - NED
- Ziye Sui - NED